Pharma major Lupin Limited (Lupin) announced that it has received approval for its Testosterone Gel, 1.62% (20.25 mg/1.25 g pump actuation), from the United States Food and Drug Administration (FDA) to market a generic version of AbbVie, Inc's (AbbVie) AndroGel 1.62%.
Lupin's Testosterone Gel, 1.62% (20.25 mg/1.25 g pump actuation), is the generic equivalent of AbbVie's AndroGel, 1.62%. It is indicated for replacement therapy in males for conditions assoc iated with a deficiency or absence of endogenous testosterone:
- Primary hypogonadism (congenital or acquired) and
- Hypogonadotropic hypogonadism (congenital or acquired)
Testosterone Gel, 1.62% (20.25 mg/1.25 g pump actuation}, (RLD: AndroGel) had annual sales of approximately USD 893 million in the US (IQVIA MAT December 2018}.
Shares of LUPIN LTD. was last trading in BSE at Rs.803.95 as compared to the previous close of Rs. 809.25. The total number of shares traded during the day was 101054 in over 2323 trades.
The stock hit an intraday high of Rs. 817.25 and intraday low of 799.4. The net turnover during the day was Rs. 81650152.